Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

Lisa Xingguang LeeThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Ping ZhouThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Cindy VargaThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Teresa FogarenThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Katelynn HoTufts University School of Medicine, Boston, MA, USA

Xun MaThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA

Melissa WarnerThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA

Denis ToskicThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA

http://orcid.org/0000-0002-3340-762X

Adin KugelmassThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA

Raymond L. ComenzoThe John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Boston, MA, USA;Department of Medicine, Tufts Medical Center, Boston, MA, USA;Department of Pathology and Clinical Laboratory Medicine, Tufts Medical Center, Boston, MA, USACorrespondence[email protected]

http://orcid.org/0000-0002-6255-5824

show all

References

Palladini G, Milani P, Foli A, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018;131:525–532.
PubMed Web of Science ®Google Scholar
Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219.
PubMed Web of Science ®Google Scholar
Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900–902.
PubMed Web of Science ®Google Scholar
Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–4549.
PubMed Web of Science ®Google Scholar
Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood. 2006;107:3489–3491.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date